DOCSLIB.ORG

Mouse Zcchc2 Knockout Project (CRISPR/Cas9)

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Mouse Zcchc2 Knockout Project (CRISPR/Cas9) https://www.alphaknockout.com Mouse Zcchc2 Knockout Project (CRISPR/Cas9) Objective: To create a Zcchc2 knockout Mouse model (C57BL/6J) by CRISPR/Cas-mediated genome engineering. Strategy summary: The Zcchc2 gene (NCBI Reference Sequence: NM_001122675 ; Ensembl: ENSMUSG00000038866 ) is located on Mouse chromosome 1. 13 exons are identified, with the ATG start codon in exon 1 and the TGA stop codon in exon 13 (Transcript: ENSMUST00000119166). Exon 3~5 will be selected as target site. Cas9 and gRNA will be co-injected into fertilized eggs for KO Mouse production. The pups will be genotyped by PCR followed by sequencing analysis. Note: Exon 3 starts from about 29.75% of the coding region. Exon 3~5 covers 7.56% of the coding region. The size of effective KO region: ~9824 bp. The KO region does not have any other known gene. Page 1 of 9 https://www.alphaknockout.com Overview of the Targeting Strategy Wildtype allele 5' gRNA region gRNA region 3' 1 3 4 5 13 Legends Exon of mouse Zcchc2 Knockout region Page 2 of 9 https://www.alphaknockout.com Overview of the Dot Plot (up) Window size: 15 bp Forward Reverse Complement Sequence 12 Note: The 2000 bp section upstream of Exon 3 is aligned with itself to determine if there are tandem repeats. No significant tandem repeat is found in the dot plot matrix. So this region is suitable for PCR screening or sequencing analysis. Overview of the Dot Plot (down) Window size: 15 bp Forward Reverse Complement Sequence 12 Note: The 2000 bp section downstream of Exon 5 is aligned with itself to determine if there are tandem repeats. Tandem repeats are found in the dot plot matrix. The gRNA site is selected outside of these tandem repeats. Page 3 of 9 https://www.alphaknockout.com Overview of the GC Content Distribution (up) Window size: 300 bp Sequence 12 Summary: Full Length(2000bp) | A(24.4% 488) | C(23.25% 465) | T(32.95% 659) | G(19.4% 388) Note: The 2000 bp section upstream of Exon 3 is analyzed to determine the GC content. No significant high GC-content region is found. So this region is suitable for PCR screening or sequencing analysis. Overview of the GC Content Distribution (down) Window size: 300 bp Sequence 12 Summary: Full Length(2000bp) | A(26.9% 538) | C(18.8% 376) | T(24.45% 489) | G(29.85% 597) Note: The 2000 bp section downstream of Exon 5 is analyzed to determine the GC content. No significant high GC-content region is found. So this region is suitable for PCR screening or sequencing analysis. Page 4 of 9 https://www.alphaknockout.com BLAT Search Results (up) QUERY SCORE START END QSIZE IDENTITY CHROM STRAND START END SPAN -------------------------------------------------------------------------------------------------------------- browser details YourSeq 2000 1 2000 2000 100.0% chr1 + 106002101 106004100 2000 browser details YourSeq 64 1498 1571 2000 97.2% chr11 - 6215317 6215402 86 browser details YourSeq 59 1244 1568 2000 69.5% chr6 + 82424034 82424137 104 browser details YourSeq 58 1445 1568 2000 94.1% chr5 - 26594081 26594233 153 browser details YourSeq 57 1504 1566 2000 96.9% chr13 - 114049381 114049448 68 browser details YourSeq 57 1505 1591 2000 93.9% chr14 + 75749600 75750105 506 browser details YourSeq 57 1517 1587 2000 88.9% chr14 + 34492236 34492303 68 browser details YourSeq 56 1505 1584 2000 95.2% chr7 + 144307145 144307233 89 browser details YourSeq 56 1503 1582 2000 90.8% chr18 + 62795340 62795418 79 browser details YourSeq 56 1504 1588 2000 88.9% chr16 + 44330855 44330936 82 browser details YourSeq 55 1510 1587 2000 92.2% chr4 - 142700959 142701036 78 browser details YourSeq 53 1504 1577 2000 94.9% chr11 + 72821442 72821518 77 browser details YourSeq 52 1504 1588 2000 77.6% chrX + 38887631 38887690 60 browser details YourSeq 52 1504 1568 2000 90.0% chr2 + 163343871 163343934 64 browser details YourSeq 51 1504 1562 2000 95.0% chr12 + 112640277 112640340 64 browser details YourSeq 50 1502 1566 2000 93.3% chr9 + 107990896 107990965 70 browser details YourSeq 50 1508 1568 2000 91.9% chr1 + 34390722 34390786 65 browser details YourSeq 49 1504 1565 2000 96.3% chrX + 164231754 164231817 64 browser details YourSeq 49 1505 1560 2000 98.1% chr17 + 32937850 32937910 61 browser details YourSeq 48 1501 1591 2000 98.1% chr11 + 3673169 3673261 93 Note: The 2000 bp section upstream of Exon 3 is BLAT searched against the genome. No significant similarity is found. BLAT Search Results (down) QUERY SCORE START END QSIZE IDENTITY CHROM STRAND START END SPAN ----------------------------------------------------------------------------------------------- browser details YourSeq 2000 1 2000 2000 100.0% chr1 + 106011816 106013815 2000 browser details YourSeq 50 687 775 2000 94.6% chr1 + 33726408 33726838 431 browser details YourSeq 44 709 775 2000 91.7% chr6 - 38521405 38521470 66 browser details YourSeq 44 692 771 2000 84.4% chr7 + 3165586 3165673 88 browser details YourSeq 43 714 775 2000 95.8% chr3 - 112628625 112628694 70 browser details YourSeq 42 691 761 2000 92.0% chr1 + 167260820 167260932 113 browser details YourSeq 40 714 771 2000 97.7% chr5 + 48603556 48603621 66 browser details YourSeq 39 704 760 2000 95.3% chr3 + 90473207 90473270 64 browser details YourSeq 39 692 760 2000 86.8% chr11 + 14095726 14095802 77 browser details YourSeq 36 714 775 2000 95.0% chr18 + 67777222 67777287 66 browser details YourSeq 34 696 775 2000 87.0% chr8 - 69904906 69904986 81 browser details YourSeq 33 709 802 2000 97.2% chr1 + 64957396 64957669 274 browser details YourSeq 32 689 730 2000 88.1% chr15 - 80828875 80828916 42 browser details YourSeq 32 689 774 2000 67.6% chr11 + 94306979 94307062 84 browser details YourSeq 31 692 728 2000 91.9% chr7 - 122094360 122094396 37 browser details YourSeq 31 709 761 2000 91.9% chr16 - 10158411 10158471 61 browser details YourSeq 31 746 778 2000 97.0% chr11 + 95650086 95650118 33 browser details YourSeq 30 748 777 2000 100.0% chr2 + 73800611 73800640 30 browser details YourSeq 29 692 728 2000 96.8% chr3 - 88605269 88605306 38 browser details YourSeq 29 692 728 2000 89.2% chr15 - 81808805 81808841 37 Note: The 2000 bp section downstream of Exon 5 is BLAT searched against the genome. No significant similarity is found. Page 5 of 9 https://www.alphaknockout.com Gene and protein information: Zcchc2 zinc finger, CCHC domain containing 2 [ Mus musculus (house mouse) ] Gene ID: 227449, updated on 12-Aug-2019 Gene summary Official Symbol Zcchc2 provided by MGI Official Full Name zinc finger, CCHC domain containing 2 provided by MGI Primary source MGI:MGI:2444114 See related Ensembl:ENSMUSG00000038866 Gene type protein coding RefSeq status VALIDATED Organism Mus musculus Lineage Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae; Murinae; Mus; Mus Also known as AW212015; 9930114B20Rik Expression Ubiquitous expression in testis adult (RPKM 19.4), thymus adult (RPKM 8.8) and 28 other tissues See more Orthologs human all Genomic context Location: 1; 1 E2.1 See Zcchc2 in Genome Data Viewer Exon count: 14 Annotation release Status Assembly Chr Location 108 current GRCm38.p6 (GCF_000001635.26) 1 NC_000067.6 (105990390..106034077) Build 37.2 previous assembly MGSCv37 (GCF_000001635.18) 1 NC_000067.5 (107886983..107930654) Chromosome 1 - NC_000067.6 Page 6 of 9 https://www.alphaknockout.com Transcript information: This gene has 5 transcripts Gene: Zcchc2 ENSMUSG00000038866 Description zinc finger, CCHC domain containing 2 [Source:MGI Symbol;Acc:MGI:2444114] Gene Synonyms 9930114B20Rik Location Chromosome 1: 105,990,406-106,034,074 forward strand. GRCm38:CM000994.2 About this gene This gene has 5 transcripts (splice variants), 212 orthologues, 1 paralogue and is a member of 1 Ensembl protein family. Transcripts Name Transcript ID bp Protein Translation ID Biotype CCDS UniProt Flags Zcchc2- ENSMUST00000119166.7 6368 1155aa ENSMUSP00000113128.1 Protein coding CCDS48336 Q69ZB8 TSL:1 202 GENCODE basic APPRIS ALT2 Zcchc2- ENSMUST00000118196.7 5796 1166aa ENSMUSP00000113974.1 Protein coding CCDS48335 Q69ZB8 TSL:5 201 GENCODE basic APPRIS P4 Zcchc2- ENSMUST00000186983.6 3455 758aa ENSMUSP00000141148.1 Protein coding - A0A087WSQ9 CDS 5' 204 incomplete TSL:1 Zcchc2- ENSMUST00000188954.6 770 257aa ENSMUSP00000139971.1 Protein coding - A0A087WPY9 CDS 5' and 3' 205 incomplete TSL:3 Zcchc2- ENSMUST00000131830.2 601 79aa ENSMUSP00000140540.1 Nonsense mediated - A0A087WRA5 CDS 5' 203 decay incomplete TSL:3 Page 7 of 9 https://www.alphaknockout.com 63.67 kb Forward strand 105.99Mb 106.00Mb 106.01Mb 106.02Mb 106.03Mb 106.04Mb Genes (Comprehensive set... Zcchc2-201 >protein coding Zcchc2-202 >protein coding Zcchc2-204 >protein coding Zcchc2-205 >protein coding Zcchc2-203 >nonsense mediated decay Contigs < AC132123.3 AC099640.6 > Genes < Gm7160-201lncRNA (Comprehensive set... < Gm7160-202lncRNA Regulatory Build 105.99Mb 106.00Mb 106.01Mb 106.02Mb 106.03Mb 106.04Mb Reverse strand 63.67 kb Regulation Legend CTCF Enhancer Open Chromatin Promoter Promoter Flank Transcription Factor Binding Site Gene Legend Protein Coding merged Ensembl/Havana Ensembl protein coding Non-Protein Coding RNA gene processed transcript Page 8 of 9 https://www.alphaknockout.com Transcript: ENSMUST00000119166 43.38 kb Forward strand Zcchc2-202 >protein coding ENSMUSP00000113... MobiDB lite Low complexity (Seg) Superfamily PX domain superfamily Zinc finger, CCHC-type superfamily SMART Zinc finger, CCHC-type Pfam Zinc finger, CCHC-type PROSITE profiles Zinc finger, CCHC-type PANTHER PTHR46939 Gene3D PX domain superfamily 4.10.60.10 All sequence SNPs/i... Sequence variants (dbSNP and all other sources) Variant Legend inframe insertion missense variant splice region variant synonymous variant Scale bar 0 100 200 300 400 500 600 700 800 900 1000 1155 We wish to acknowledge the following valuable scientific information resources: Ensembl, MGI, NCBI, UCSC. Page 9 of 9.
Load more

Recommended publications
  • Ggbio: Visualization Toolkits for Genomic Data
    ggbio: visualization toolkits for genomic data 1 Tengfei Yin [email protected] May 19, 2021 Contents 1 Getting started............................4 1.1 Citation.................................4 1.2 Introduction ..............................4 2 Case study: building your first tracks..............6 2.1 Add an ideogram track ........................6 2.2 Add a gene model track .......................7 2.2.1 Introduction ...........................7 2.2.2 Make gene model from OrganismDb object ............7 2.2.3 Make gene model from TxDb object ................ 11 2.2.4 Make gene model from EnsDb object ............... 12 2.2.5 Make gene model from GRangesList object ............ 16 2.3 Add a reference track ........................ 19 2.3.1 Semantic zoom.......................... 19 2.4 Add an alignment track ....................... 20 2.5 Add a variants track ......................... 25 2.6 Building your tracks ......................... 28 3 Simple navigation .......................... 30 4 Overview plots............................ 32 4.1 how to make circular plots ...................... 32 4.1.1 Introduction ........................... 32 4.1.2 Buidling circular plot layer by layer................. 32 2 ggbio:visualization toolkits for genomic data 4.1.3 Complex arragnment of plots ................... 39 4.2 How to make grandlinear plots ................... 41 4.2.1 Introduction ........................... 41 4.2.2 Corrdinate genome ........................ 43 4.2.3 Convenient plotGrandLinear function ............... 43 4.2.4 How to highlight some points? .................. 45 4.3 How to make stacked karyogram overview plots ......... 46 4.3.1 Introduction ........................... 46 4.3.2 Create karyogram temlate .................... 46 4.3.3 Add data on karyogram layout................... 48 4.3.4 Add more data using layout_karyogram function .......... 51 4.3.5 More flexible layout of karyogram ................
    [Show full text]
  • Precise and Sustained Gene Silencing in CD4+ Cells Using Designer Epigenome Modifiers As a Therapeutic Approach to Treat HIV Infection
    Precise and sustained gene silencing in CD4+ cells using designer epigenome modifiers as a therapeutic approach to treat HIV infection Inaugural-Dissertation to obtain the Doctoral Degree Faculty of Biology, Albert-Ludwigs-Universität Freiburg im Breisgau presented by Tafadzwa Mlambo born in Harare, Zimbabwe Freiburg im Breisgau February 2018 Dekanin: Prof. Dr. Bettina Warscheid Promotionsvorsitzender: Prof. Dr. Andreas Hiltbrunner Betreuer der Arbeit: Dr. Claudio Mussolino Referent: Prof. Dr. Toni Cathomen Ko-Referent: Prof. Dr. Peter Stäheli Drittprüfer: Dr. Giorgos Pyrowolakis Datum der mündlichen Prüfung: 27.04.2018 iii Table of Contents TABLE OF CONTENTS TABLE OF CONTENTS III ABSTRACT VIII 1. INTRODUCTION 11 1.1 HIV BURDEN AND EPIDEMIOLOGY 11 1.2 HIV LIFE CYCLE AND TROPISM 12 1.3 HIV TREATMENT 14 1.4 CCR5 AND CXCR4 AS TARGETS OF ANTI-HIV THERAPY 15 1.5 DESIGNER NUCLEASE TECHNOLOGY 17 1.5.1 Zinc finger nucleases 19 1.5.2 Transcription activator-like effector nucleases 20 1.5.3 RNA-guided endonucleases 21 1.6 HIV GENE THERAPY 22 1.7 OFF-TARGET EFFECTS 25 1.8 DELIVERY 27 1.9 EPIGENETIC REGULATION 30 1.9.1 Gene expression 30 1.9.2 Transcriptional regulation of gene expression 31 1.9.3 Targeted transcription activation 32 1.9.4 Targeted transcription repression 33 1.9.5 Epigenome editing 36 1.9.6 DNA methylation 38 iv Table of Contents 1.9.7 Designer epigenome modifiers 40 1.10 AIM AND OBJECTIVES OF PHD THESIS 42 2. MATERIALS AND METHODS 44 2.1 STANDARD MOLECULAR BIOLOGY METHODS 44 2.1.1 Restriction digest 44 2.1.2 Ligation 44 2.1.3 Polymerase
    [Show full text]
  • (P -Value<0.05, Fold Change≥1.4), 4 Vs. 0 Gy Irradiation
    Table S1: Significant differentially expressed genes (P -Value<0.05, Fold Change≥1.4), 4 vs. 0 Gy irradiation Genbank Fold Change P -Value Gene Symbol Description Accession Q9F8M7_CARHY (Q9F8M7) DTDP-glucose 4,6-dehydratase (Fragment), partial (9%) 6.70 0.017399678 THC2699065 [THC2719287] 5.53 0.003379195 BC013657 BC013657 Homo sapiens cDNA clone IMAGE:4152983, partial cds. [BC013657] 5.10 0.024641735 THC2750781 Ciliary dynein heavy chain 5 (Axonemal beta dynein heavy chain 5) (HL1). 4.07 0.04353262 DNAH5 [Source:Uniprot/SWISSPROT;Acc:Q8TE73] [ENST00000382416] 3.81 0.002855909 NM_145263 SPATA18 Homo sapiens spermatogenesis associated 18 homolog (rat) (SPATA18), mRNA [NM_145263] AA418814 zw01a02.s1 Soares_NhHMPu_S1 Homo sapiens cDNA clone IMAGE:767978 3', 3.69 0.03203913 AA418814 AA418814 mRNA sequence [AA418814] AL356953 leucine-rich repeat-containing G protein-coupled receptor 6 {Homo sapiens} (exp=0; 3.63 0.0277936 THC2705989 wgp=1; cg=0), partial (4%) [THC2752981] AA484677 ne64a07.s1 NCI_CGAP_Alv1 Homo sapiens cDNA clone IMAGE:909012, mRNA 3.63 0.027098073 AA484677 AA484677 sequence [AA484677] oe06h09.s1 NCI_CGAP_Ov2 Homo sapiens cDNA clone IMAGE:1385153, mRNA sequence 3.48 0.04468495 AA837799 AA837799 [AA837799] Homo sapiens hypothetical protein LOC340109, mRNA (cDNA clone IMAGE:5578073), partial 3.27 0.031178378 BC039509 LOC643401 cds. [BC039509] Homo sapiens Fas (TNF receptor superfamily, member 6) (FAS), transcript variant 1, mRNA 3.24 0.022156298 NM_000043 FAS [NM_000043] 3.20 0.021043295 A_32_P125056 BF803942 CM2-CI0135-021100-477-g08 CI0135 Homo sapiens cDNA, mRNA sequence 3.04 0.043389246 BF803942 BF803942 [BF803942] 3.03 0.002430239 NM_015920 RPS27L Homo sapiens ribosomal protein S27-like (RPS27L), mRNA [NM_015920] Homo sapiens tumor necrosis factor receptor superfamily, member 10c, decoy without an 2.98 0.021202829 NM_003841 TNFRSF10C intracellular domain (TNFRSF10C), mRNA [NM_003841] 2.97 0.03243901 AB002384 C6orf32 Homo sapiens mRNA for KIAA0386 gene, partial cds.
    [Show full text]
  • Anglemetry of Neural Axis Cell Differentiation Genes by Structural Pressurotopy of DNA Loop Strand Segment Tropy in Reference to Tissue Macro-Compliance Hemant Sarin
    Sarin Translational Medicine Communications (2019) 4:13 Translational Medicine https://doi.org/10.1186/s41231-019-0045-4 Communications RESEARCH Open Access Anglemetry of neural axis cell differentiation genes by structural pressurotopy of DNA loop strand segment tropy in reference to tissue macro-compliance Hemant Sarin Abstract Background: Even as the eukaryotic stranded DNA is known to heterochromatinize at the nuclear envelope in response to mechanical strain, the precise mechanistic basis for alterations in chromatin gene transcription in differentiating cell lineages has been difficult to determine due to limited spatial resolution for detection of shifts in reference to a specific gene in vitro. In this study, heterochromatin shift during euchromatin gene transcription has been studied by parallel determinations of DNA strand loop segmentation tropy nano-compliance (esebssiwaagoTQ units, linear nl), gene positioning angulation in linear normal two- 0 dimensional (2-D) z, y-vertical plane (anglemetry, ), horizontal alignment to the z, x-plane (vectormetry; mA, mM,a.u.),andby pressuromodulation mapping of differentiated neuron cell sub-class operating range for neuroaxis gene expression in reference to tissue macro-compliance (Peff). Methods: The esebssiwaagoTQ effectivepressureunit(Peff) maxima and minima for horizontal gene intergene base segment tropy loop alignment were determined (n = 224); the Peff esebssiwaagoTQ quotient were determined (n =28)foranalysisof gene intergene base loop segment tropy structure nano-compliance (n = 28; n = 188); and gene positioning anglemetry and vectormetry was performed (n = 42). The sebs intercept-to-sebssiwa intercept quotient for linear normalization was determined (bsebs/bsebssiwa) by exponential plotting of sub-episode block sum (sebs) (x1, y1; x2, y2) and sub-episode block sum split integrated weighted average (sebssiwa) functions was performed, and the sebs – sebssiwa function residuals were determined.
    [Show full text]
  • Plasma Fatty Acid Ratios Affect Blood Gene Expression Profiles - a Cross-Sectional Study of the Norwegian Women and Cancer Post-Genome Cohort
    Plasma Fatty Acid Ratios Affect Blood Gene Expression Profiles - A Cross-Sectional Study of the Norwegian Women and Cancer Post-Genome Cohort Karina Standahl Olsen1*, Christopher Fenton2, Livar Frøyland3, Marit Waaseth4, Ruth H. Paulssen2, Eiliv Lund1 1 Department of Community Medicine, University of Tromsø, Tromsø, Norway, 2 Department of Clinical Medicine, University of Tromsø, Tromsø, Norway, 3 National Institute of Nutrition and Seafood Research (NIFES), Bergen, Norway, 4 Department of Pharmacy, University of Tromsø, Tromsø, Norway Abstract High blood concentrations of n-6 fatty acids (FAs) relative to n-3 FAs may lead to a ‘‘physiological switch’’ towards permanent low-grade inflammation, potentially influencing the onset of cardiovascular and inflammatory diseases, as well as cancer. To explore the potential effects of FA ratios prior to disease onset, we measured blood gene expression profiles and plasma FA ratios (linoleic acid/alpha-linolenic acid, LA/ALA; arachidonic acid/eicosapentaenoic acid, AA/EPA; and total n-6/n-3) in a cross-section of middle-aged Norwegian women (n = 227). After arranging samples from the highest values to the lowest for all three FA ratios (LA/ALA, AA/EPA and total n-6/n-3), the highest and lowest deciles of samples were compared. Differences in gene expression profiles were assessed by single-gene and pathway-level analyses. The LA/ALA ratio had the largest impact on gene expression profiles, with 135 differentially expressed genes, followed by the total n-6/ n-3 ratio (125 genes) and the AA/EPA ratio (72 genes). All FA ratios were associated with genes related to immune processes, with a tendency for increased pro-inflammatory signaling in the highest FA ratio deciles.
    [Show full text]
  • Human Induced Pluripotent Stem Cell–Derived Podocytes Mature Into Vascularized Glomeruli Upon Experimental Transplantation
    BASIC RESEARCH www.jasn.org Human Induced Pluripotent Stem Cell–Derived Podocytes Mature into Vascularized Glomeruli upon Experimental Transplantation † Sazia Sharmin,* Atsuhiro Taguchi,* Yusuke Kaku,* Yasuhiro Yoshimura,* Tomoko Ohmori,* ‡ † ‡ Tetsushi Sakuma, Masashi Mukoyama, Takashi Yamamoto, Hidetake Kurihara,§ and | Ryuichi Nishinakamura* *Department of Kidney Development, Institute of Molecular Embryology and Genetics, and †Department of Nephrology, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan; ‡Department of Mathematical and Life Sciences, Graduate School of Science, Hiroshima University, Hiroshima, Japan; §Division of Anatomy, Juntendo University School of Medicine, Tokyo, Japan; and |Japan Science and Technology Agency, CREST, Kumamoto, Japan ABSTRACT Glomerular podocytes express proteins, such as nephrin, that constitute the slit diaphragm, thereby contributing to the filtration process in the kidney. Glomerular development has been analyzed mainly in mice, whereas analysis of human kidney development has been minimal because of limited access to embryonic kidneys. We previously reported the induction of three-dimensional primordial glomeruli from human induced pluripotent stem (iPS) cells. Here, using transcription activator–like effector nuclease-mediated homologous recombination, we generated human iPS cell lines that express green fluorescent protein (GFP) in the NPHS1 locus, which encodes nephrin, and we show that GFP expression facilitated accurate visualization of nephrin-positive podocyte formation in
    [Show full text]
  • MIKULASOVA Et Al. MMEJ DRIVES 8Q24 REARRANGEMENTS in MYELOMA
    MIKULASOVA et al. MMEJ DRIVES 8q24 REARRANGEMENTS IN MYELOMA Microhomology-mediated end joining drives complex rearrangements and over-expression of MYC and PVT1 in multiple myeloma Authors Aneta Mikulasova1,2, Cody Ashby1, Ruslana G. Tytarenko1, Pingping Qu3, Adam Rosenthal3, Judith A. Dent1, Katie R. Ryan1, Michael A. Bauer1, Christopher P. Wardell1, Antje Hoering3, Konstantinos Mavrommatis4, Matthew Trotter5, Shayu Deshpande1, Erming Tian1, Jonathan Keats6, Daniel Auclair7, Graham H. Jackson8, Faith E. Davies1, Anjan Thakurta4, Gareth J. Morgan1, and Brian A. Walker1 Affiliations 1Myeloma Center, University of Arkansas for Medical Sciences, Little Rock, AR, USA 2Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom 3Cancer Research and Biostatistics, Seattle, WA, USA 4Celgene Corporation, Summit, NJ, USA 5Celgene Institute for Translational Research Europe, Seville, Spain 6Translational Genomics Research Institute, Phoenix, AZ, USA. 7Multiple Myeloma Research Foundation, Norwalk, CT, USA. 8Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, United Kingdom MIKULASOVA et al. MMEJ DRIVES 8q24 REARRANGEMENTS IN MYELOMA Contents Supplementary Methods ............................................................................................................... 2 Data Analysis .............................................................................................................................. 2 External Datasets ......................................................................................................................
    [Show full text]
  • Elucidating the Genetic Architecture of Reproductive Ageing in the Japanese Population
    bioRxiv preprint doi: https://doi.org/10.1101/182717; this version posted August 30, 2017. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. 1 Title: Elucidating the genetic architecture of reproductive ageing in the Japanese population Momoko Horikoshi*1, Felix R. Day*2, Yoichiro Kamatani3,4, Makoto Hirata5, Masato Akiyama3, Koichi Matsuda5, Hollis Wright6, Carlos A. Toro6, Sergio R. Ojeda7, Alejandro Lomniczi6, Michiaki Kubo*8, Ken K. Ong*2 and John R. B. Perry*2 1. Laboratory for Endocrinology, Metabolism and Kidney Diseases, RIKEN Centre for Integrative Medical Sciences, Yokohama 230-0045, Japan 2. MRC Epidemiology Unit, University of Cambridge School of Clinical Medicine, Institute of Metabolic Science, Cambridge Biomedical Campus, Cambridge, UK. 3. Laboratory for Statistical Analysis, RIKEN Center for Integrative Medical Sciences, Yokohama 230-0045, Japan 4. Center for Genomic Medicine, Kyoto University Graduate School of Medicine, Kyoto 606- 8507, Japan. 5. Laboratory of Genome Technology, Human Genome Center, Institute of Medical Science, The University of Tokyo, Tokyo 108-8639, Japan 6. Primate Genetics Section / Division of Neuroscience, Oregon National Primate Research Center, Oregon Health and Sciences University, Beaverton, OR 97006, USA 7. Division of Neuroscience, Oregon National Primate Research Center, Oregon Health and Sciences University, Beaverton, OR 97006, USA 8. RIKEN Center for Integrative Medical Sciences, Yokohama 230-0045, Japan * denotes equal contributions Correspondence to Momoko Horikoshi ([email protected]) and John R.B.
    [Show full text]
  • Nº Ref Uniprot Proteína Péptidos Identificados Por MS/MS 1 P01024
    Document downloaded from http://www.elsevier.es, day 26/09/2021. This copy is for personal use. Any transmission of this document by any media or format is strictly prohibited. Nº Ref Uniprot Proteína Péptidos identificados 1 P01024 CO3_HUMAN Complement C3 OS=Homo sapiens GN=C3 PE=1 SV=2 por 162MS/MS 2 P02751 FINC_HUMAN Fibronectin OS=Homo sapiens GN=FN1 PE=1 SV=4 131 3 P01023 A2MG_HUMAN Alpha-2-macroglobulin OS=Homo sapiens GN=A2M PE=1 SV=3 128 4 P0C0L4 CO4A_HUMAN Complement C4-A OS=Homo sapiens GN=C4A PE=1 SV=1 95 5 P04275 VWF_HUMAN von Willebrand factor OS=Homo sapiens GN=VWF PE=1 SV=4 81 6 P02675 FIBB_HUMAN Fibrinogen beta chain OS=Homo sapiens GN=FGB PE=1 SV=2 78 7 P01031 CO5_HUMAN Complement C5 OS=Homo sapiens GN=C5 PE=1 SV=4 66 8 P02768 ALBU_HUMAN Serum albumin OS=Homo sapiens GN=ALB PE=1 SV=2 66 9 P00450 CERU_HUMAN Ceruloplasmin OS=Homo sapiens GN=CP PE=1 SV=1 64 10 P02671 FIBA_HUMAN Fibrinogen alpha chain OS=Homo sapiens GN=FGA PE=1 SV=2 58 11 P08603 CFAH_HUMAN Complement factor H OS=Homo sapiens GN=CFH PE=1 SV=4 56 12 P02787 TRFE_HUMAN Serotransferrin OS=Homo sapiens GN=TF PE=1 SV=3 54 13 P00747 PLMN_HUMAN Plasminogen OS=Homo sapiens GN=PLG PE=1 SV=2 48 14 P02679 FIBG_HUMAN Fibrinogen gamma chain OS=Homo sapiens GN=FGG PE=1 SV=3 47 15 P01871 IGHM_HUMAN Ig mu chain C region OS=Homo sapiens GN=IGHM PE=1 SV=3 41 16 P04003 C4BPA_HUMAN C4b-binding protein alpha chain OS=Homo sapiens GN=C4BPA PE=1 SV=2 37 17 Q9Y6R7 FCGBP_HUMAN IgGFc-binding protein OS=Homo sapiens GN=FCGBP PE=1 SV=3 30 18 O43866 CD5L_HUMAN CD5 antigen-like OS=Homo
    [Show full text]
  • Supplementary Table 1: Genes Located on Chromosome 18P11-18Q23, an Area Significantly Linked to TMPRSS2-ERG Fusion
    Supplementary Table 1: Genes located on Chromosome 18p11-18q23, an area significantly linked to TMPRSS2-ERG fusion Symbol Cytoband Description LOC260334 18p11 HSA18p11 beta-tubulin 4Q pseudogene IL9RP4 18p11.3 interleukin 9 receptor pseudogene 4 LOC100132166 18p11.32 hypothetical LOC100132166 similar to Rho-associated protein kinase 1 (Rho- associated, coiled-coil-containing protein kinase 1) (p160 LOC727758 18p11.32 ROCK-1) (p160ROCK) (NY-REN-35 antigen) ubiquitin specific peptidase 14 (tRNA-guanine USP14 18p11.32 transglycosylase) THOC1 18p11.32 THO complex 1 COLEC12 18pter-p11.3 collectin sub-family member 12 CETN1 18p11.32 centrin, EF-hand protein, 1 CLUL1 18p11.32 clusterin-like 1 (retinal) C18orf56 18p11.32 chromosome 18 open reading frame 56 TYMS 18p11.32 thymidylate synthetase ENOSF1 18p11.32 enolase superfamily member 1 YES1 18p11.31-p11.21 v-yes-1 Yamaguchi sarcoma viral oncogene homolog 1 LOC645053 18p11.32 similar to BolA-like protein 2 isoform a similar to 26S proteasome non-ATPase regulatory LOC441806 18p11.32 subunit 8 (26S proteasome regulatory subunit S14) (p31) ADCYAP1 18p11 adenylate cyclase activating polypeptide 1 (pituitary) LOC100130247 18p11.32 similar to cytochrome c oxidase subunit VIc LOC100129774 18p11.32 hypothetical LOC100129774 LOC100128360 18p11.32 hypothetical LOC100128360 METTL4 18p11.32 methyltransferase like 4 LOC100128926 18p11.32 hypothetical LOC100128926 NDC80 homolog, kinetochore complex component (S. NDC80 18p11.32 cerevisiae) LOC100130608 18p11.32 hypothetical LOC100130608 structural maintenance
    [Show full text]
  • Transcriptional Regulators Are Upregulated in the Substantia Nigra
    Journal of Emerging Investigators Transcriptional Regulators are Upregulated in the Substantia Nigra of Parkinson’s Disease Patients Marianne Cowherd1 and Inhan Lee2 1Community High School, Ann Arbor, MI 2miRcore, Ann Arbor, MI Summary neurological conditions is an established practice (3). Parkinson’s disease (PD) affects approximately 10 Significant gene expression dysregulation in the SN and million people worldwide with tremors, bradykinesia, in the striatum has been described, particularly decreased apathy, memory loss, and language issues. Though such expression in PD synapses. Protein degradation has symptoms are due to the loss of the substantia nigra (SN) been found to be upregulated (4). Mutations in SNCA brain region, the ultimate causes and complete pathology are unknown. To understand the global gene expression (5), LRRK2 (6), and GBA (6) have also been identified changes in SN, microarray expression data from the SN as familial markers of PD. SNCA encodes alpha- tissue of 9 controls and 16 PD patients were compared, synuclein, a protein found in presynaptic terminals that and significantly upregulated and downregulated may regulate vesicle presence and dopamine release. genes were identified. Among the upregulated genes, Eighteen SNCA mutations have been associated with a network of 33 interacting genes centered around the PD and, although the exact pathogenic mechanism is cAMP-response element binding protein (CREBBP) was not confirmed, mutated alpha-synuclein is the major found. The downstream effects of increased CREBBP- component of protein aggregates, called Lewy bodies, related transcription and the resulting protein levels that are often found in PD brains and may contribute may result in PD symptoms, making CREBBP a potential therapeutic target due to its central role in the interactive to cell death.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2016/0264934 A1 GALLOURAKIS Et Al
    US 20160264934A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2016/0264934 A1 GALLOURAKIS et al. (43) Pub. Date: Sep. 15, 2016 (54) METHODS FOR MODULATING AND Publication Classification ASSAYING MI6AIN STEM CELL POPULATIONS (51) Int. Cl. CI2N5/0735 (2006.01) (71) Applicants: THE GENERAL, HOSPITAL AOIN I/02 (2006.01) CORPORATION, Boston, MA (US); CI2O I/68 (2006.01) The Regents of the University of GOIN 33/573 (2006.01) California, Oakland, CA (US) CI2N 5/077 (2006.01) CI2N5/0793 (2006.01) (72) Inventors: Cosmas GIALLOURAKIS, Boston, (52) U.S. Cl. MA (US); Alan C. MULLEN, CPC ............ CI2N5/0606 (2013.01); CI2N5/0657 Brookline, MA (US); Yi XING, (2013.01); C12N5/0619 (2013.01); C12O Torrance, CA (US) I/6888 (2013.01); G0IN33/573 (2013.01); A0IN I/0226 (2013.01); C12N 2501/72 (73) Assignees: THE GENERAL, HOSPITAL (2013.01); C12N 2506/02 (2013.01); C12O CORPORATION, Boston, MA (US); 2600/158 (2013.01); C12Y 201/01062 The Regents of the University of (2013.01); C12Y 201/01 (2013.01) California, Oakland, CA (US) (57) ABSTRACT (21) Appl. No.: 15/067,780 The present invention generally relates to methods, assays and kits to maintain a human stem cell population in an (22) Filed: Mar 11, 2016 undifferentiated state by inhibiting the expression or function of METTL3 and/or METTL4, and mA fingerprint methods, assays, arrays and kits to assess the cell state of a human stem Related U.S. Application Data cell population by assessing mA levels (e.g. mA peak inten (60) Provisional application No.
    [Show full text]